PTAFR

Platelet-activating factor receptor · P25105 · PTAFR on Sugi Atlas →

29,522 patent compounds predicted against PTAFR, 19,100 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Etizolam (SCHEMBL42920)	0.74	19/20
Apafant (SCHEMBL94167)	1.00	18/20
Bepafant (SCHEMBL94512)	1.00	18/20
Apafant (SCHEMBL1189235)	0.91	18/20
Israpafant (SCHEMBL121587)	0.69	18/20
Israpafant (SCHEMBL121588)	0.69	18/20
Fletazepam (SCHEMBL1004270)	0.47	18/20
Brotizolam (SCHEMBL44067)	1.00	16/20
Brotizolam (SCHEMBL1005083)	0.64	15/20
Rocepafant (SCHEMBL1065775)	0.52	13/20
SCHEMBL86872	0.45	12/20
Bromide (SCHEMBL82425)	0.44	12/20
SCHEMBL1231485	0.56	11/20
SCHEMBL1231486	0.56	11/20
Azatadine (SCHEMBL450674)	0.69	10/20
Azatadine (SCHEMBL450675)	0.69	10/20
Azatadine (SCHEMBL450676)	0.69	10/20
SCHEMBL1110613	1.00	8/20
Triazolam (SCHEMBL29228)	0.79	8/20
Azatadine (SCHEMBL3721)	0.72	8/20

Clinical trials — most relevant to PTAFR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vorapaxar on Thrombin Generation and Coagulability	PHASE4	COMPLETED
Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome	PHASE4	COMPLETED
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention	PHASE4	UNKNOWN
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation	PHASE4	COMPLETED
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus	PHASE4	COMPLETED
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:	PHASE4	COMPLETED
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke	PHASE4	NOT_YET_RECRUITING
Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism	PHASE4	COMPLETED
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases	PHASE4	COMPLETED
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages	PHASE2/PHASE3	UNKNOWN
Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS	PHASE2/PHASE3	UNKNOWN
Thromboxane Receptor Antagonist to Improve Endothelial Function	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer	PHASE2	COMPLETED
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy	PHASE2	COMPLETED
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma	PHASE1	COMPLETED
Sexual Hormones and Haemostasis: Observations for Women Health	nan	UNKNOWN
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Thrombin Regulated Platelet Activation	nan	COMPLETED
Platelet Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome (HiPPO Trial)	nan	COMPLETED
PAR Regulation of Platelet Function in Diabetic Patients	nan	COMPLETED
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
Study on the Registration of Coronary Heart Disease Patients Undergoing PCI	nan	COMPLETED
Inflammation, Platelets and Sickle Cell Disease	nan	ACTIVE_NOT_RECRUITING
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme	nan	NOT_YET_RECRUITING
The Evaluation of Hemostasis in Hospitalized COVID-19 Patients	nan	UNKNOWN
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis	nan	RECRUITING
Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTAFR binder may also engage these)

Protein	Name	Similarity
Q9GK76	—	1.000	Q9GK76 →
Q9XSD4	—	1.000	Q9XSD4 →
Q9TTY5	—	1.000	Q9TTY5 →
D4A7K7	—	0.999	D4A7K7 →
P21556	—	0.998	P21556 →
Q61038	—	0.997	Q61038 →
Q3U507	—	0.997	Q3U507 →
Q62035	—	0.995	Q62035 →
Q3U6B2	—	0.995	Q3U6B2 →
A5PLE7	—	0.994	A5PLE7 →
P46002	—	0.994	P46002 →
GPR183	G-protein coupled receptor 183	0.993	landscape →
Q924T8	—	0.992	Q924T8 →
B0UXR0	—	0.991	B0UXR0 →
GPR65	G-protein coupled receptor 65	0.990	landscape →
GPR174	Probable G-protein coupled receptor 174	0.989	landscape →
B5X337	—	0.988	B5X337 →
P35366	—	0.987	P35366 →
Q99JA4	—	0.986	Q99JA4 →
P35374	—	0.985	P35374 →
Q8BFU7	—	0.985	Q8BFU7 →
Q2NNR5	—	0.985	Q2NNR5 →
P56482	—	0.984	P56482 →
Q1RMI1	—	0.984	Q1RMI1 →
Q95N02	—	0.983	Q95N02 →
P2RY10	Putative P2Y purinoceptor 10	0.983	landscape →
Q4G072	—	0.983	Q4G072 →
P56485	—	0.982	P56485 →
GPR55	G-protein coupled receptor 55	0.982	landscape →
P49685	—	0.982	P49685 →